TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Angiomax® or Unfractionated Heparin for Patients Undergoing Percutaneous Coronary Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The patient is male or female ≥ 18 years of age.~2. The patient presents with stable angina pectoris, or silent ischemia (positive stress test without chest pain).~3. The patient is scheduled for coronary angiography, with possible angioplasty.~4. The patient is able to tolerate dual anti-platelet therapy with aspirin and clopidogrel for a minimum of 30 days and is on those medications at the time of the PCI (clopidogrel may be administered during PCI or within 30 minutes post PCI).~5. The patient is able and willing to conform to the requirements of the study and voluntarily signs an Informed Consent.~6. The patient does not present with any form of illness or condition that in the investigator's opinion would impair the results of the study.~7. Women of child bearing potential must have a negative urine or serum pregnancy test prior to enrollment.~Exclusion Criteria:~1. Patients in cardiogenic shock.~2. Patients with acute coronary syndrome, which includes unstable angina, non-ST-elevation MI or STEMI.~3. Known history of heparin-induced thrombocytopenia.~4. Contraindication to unfractionated heparin, bivalirudin, or any anticoagulant or antithrombotic pharmacological agent.~5. Any significant medical condition, which in the investigator's opinion, may interfere with the patient's optimal participation in the study.~6. Pregnant women or nursing mothers.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bivalirudin (Type: ACTIVE_COMPARATOR): Anticoagulation during percutaneous coronary intervention
- Unfractionated Heparin (Type: ACTIVE_COMPARATOR): Anticoagulation during percutaneous coronary intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: WILD 5 Wellness: A 30-Day Intervention

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* students 18 years of age or older~* students enrolled in First Year Initiative Course titled, Habits of Mind, Habits of Body.~Exclusion Criteria:~* individuals who are pregnant or plan to get pregnant during the next 30 days~* students who are not enrolled in the First Year Initiative Course titled, Habits of Mind, Habits of Body.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Study Participants (Type: OTHER): The participants in this arm will engage in the WILD 5 Wellness activities combining five wellness elements including exercise, mindfulness, sleep, social connectedness and nutrition.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Conservative Treatment Versus the Surgical Treatment of Diaphyseal Fractures of Humerus

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female over 18 years~* Fracture of the humeral diaphysis~* Recent fracture (14 days or less)~* Closed fracture~* Signing of consent form~Exclusion Criteria:~* Segmental fracture of the humerus~* Fracture with proximal or distal intra articular extension~* Open fracture~* Polytrauma~* Floating elbow or shoulder~* Pathological fracture~* Simultaneous fracture of both humerus~* Associated vascular disease~* Severe neuromuscular disorders such as Parkinson, hemiparesis, myasthenia gravis, muscular dystrophy, etc. ...~* medical contraindication to surgery~* severe central neurological disease disabling patient to fill in questionnaires (senile dementia, Alzheimer's, etc ...~* Male or female unable to consent~* Any other condition which prevents the assessor from fully monitoring the patient during study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Surgical treatment (Type: ACTIVE_COMPARATOR): Patients included in the surgical group will have surgery to treat the fracture.
- Conservative treatment group (Type: ACTIVE_COMPARATOR): Patients included in the conservative group will be taken to a plaster room where a Hanging Support System(HSS) brace will be installed by a qualified technician.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed, previously untreated, cytologically/histologically confirmed de novo or secondary AML according to World Health Organization (WHO) classification (except for acute promyelocytic leukemia (APL))~* Intermediate or adverse cytogenetic risk~* Eligible for therapy with either decitabine or azacitidine~* Acceptable hematologic and organ function~Exclusion Criteria:~* AML associated with favorable risk karyotypes including inv(16), t(8;21), t(16;16), or t(15;17)~* Patients who are candidates for allogeneic stem cell transplant at the time of enrollment~* Patients with a history of one of the following myeloproliferative neoplasms: essential thrombocythemia, polycythemia vera, and primary myelofibrosis~* Received prior treatment with HMA or chemotherapy for antecedent myelodysplastic syndrome (MDS)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 33A + HMA (Type: EXPERIMENTAL): 33A plus azacitidine or decitabine
- placebo + HMA (Type: ACTIVE_COMPARATOR): placebo plus azacitidine or decitabine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of CBT-1 and Paclitaxel With Carboplatin in Patients With Advanced Inoperable Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* histological confirmed diagnosis of NSCLC~* advanced inoperable NSCLC~* have adequate renal function, serum creatinine \<2.0 mg/dL or 24 hour creatinine clearance \> 50mL/minute~* have adequate liver function defined as SGOT \<4 times the upper limit of normal (ULN) and bilirubin \<2.0 mg/dL~* have calcium \<11.0 mg/dL and albumin \>2.0g/dL~* have adequate bone marrow reserve defined as granulocyte count \>1,500/mm3, hemoglobin \>10.0 g/dL and platelets \>100,000/mm3~* if female and of child-bearing potential, agree to use one of the following methods of birth control: oral contraceptives, barrier with spermicide, intrauterine progesterone contraceptive system, levonorgestrel implant, medroxyprogesterone acetate contraceptive injection, complete abstinence from sexual intercourse~Exclusion Criteria:~* have previously received taxanes, platinums, vinca alkaloids, anthracyclines, epipodophyllotoxins or CBT-1~* have known or suspected hypersensitivity to platinum containing compounds, taxanes, polyoxyethylated castor oil, or mannitol~* have significant central nervous system disease, including history of seizures within last 3 months or psychiatric history which would impair the ability to give informed consent or prevent compliance with protocol requirements~* be eligible for curative surgery or radiotherapy.~* must not have a diagnosis and/or treatment in the past 5 years of any malignancy other than NSCLC or basal cell carcinoma of the skin~* be pregnant or nursing~* have a history of significant coronary artery disease, cardiac arrhythmias requiring treatment, history of other cardiac disease or other cardiac anomalies determined by ECG which in the judgment of the investigator would compromise the patient's ability to tolerate the therapy~* have ongoing serious infections that require parenteral antibiotics~* have clinically significant bleeding disorders~* have solid organ allograft~* have significant intercurrent disease~* have bleeding peptic ulcer disease~* have participated in any experimental study within 2 months preceding enrollment~* be using a medication that could interact adversely with CBT-1, paclitaxel, or carboplatin. Medications include:aminoglycoside antibiotics, Prilosec, Losec, Zantac

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CBT-1 (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Subject aged 18 years and older referred for evaluation of possible stroke.~2. Subject receives Computed Tomography Angiography (CTA) imaging for the assessment of stroke.~3. Subject or Legally Authorized Representative has the ability to provide informed consent and comply with the protocol.~Exclusion Criteria:~1. Head CT findings consistent with acute primary intracranial hemorrhage (ICH), etc.~2. Subjects with occlusions in the distal or posterior circulation arteries.~3. Subjects who underwent partial or full craniotomy~4. Additional intracranial pathologies present (tumor, hydrocephalus, etc.)~5. Anticipated insufficient time to acquire a complete TCD scan as described by the protocol~6. Subjects who have a physical limitation preventing placement of the system.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort X (Type: None): Phase 0 will include up to 20 subjects in Cohort X (TCD). This phase is for training and feasibility purposes only and data collected will not be used in the final analysis.
- Cohort Y (Type: None): Phase 0 will include up to 20 subjects in Cohort Y (No TCD). This phase is for training and feasibility purposes only and data collected will not be used in the final analysis.
- Cohort A (Type: None): Both Phase 1 and Phase 2 of the study will enroll Cohort A (LVO TCD). Cohort A will enroll 54 subjects in Phase 1 and 156 subjects in Phase 2
- Cohort B (Type: None): Both Phase 1 and Phase 2 of the study will enroll Cohort B (Non-LVO TCD). Cohort B will enroll 54 subjects in Phase 1 and 156 subjects in Phase 2
- Cohort C (Type: None): Both Phase 1 and Phase 2 of the study will enroll Cohort C (LVO No-TCD). Cohort C will enroll 54 subjects in Phase 1 and 156 subjects in Phase 2
- Cohort D (Type: None): Both Phase 1 and Phase 2 of the study will enroll Cohort D (Non-LVO No-TCD). Cohort D will enroll 54 subjects in Phase 1 and 156 subjects in Phase 2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mild Hypothermia and Acute Kidney Injury in Liver Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Liver transplantation from a donor after neurologic determination of death~Exclusion Criteria:~* Liver transplantation from a donor after cardiac death~* Acute liver failure~* Living-donor liver transplantation~* Simultaneous liver-kidney transplantation~* Preoperative renal replacement therapy~* Preoperative intubation~* Portopulmonary hypertension~* Machine perfusion of liver graft

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mild hypothermia & Esophageal cooling/warming device (Type: EXPERIMENTAL): The target core temperature is 34-35 °C.
- Normothermia & Esophageal cooling/warming device (Type: ACTIVE_COMPARATOR): The target core temperature is 36.5-37.5 °C.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transcranial Direct Current Stimulation (tDCS) in Chronic Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with neuropathic pain with indication of regional anaesthesiological interventions~Exclusion Criteria:~* \<18 years of age~* Pregnancy~* Police custody~* Epilepsy~* Participation in another prospective clinical intervention study within the last 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: SHAM_COMPARATOR): sham transcranial direct current stimulation (tDCS)
- cathodal stimulation (Type: EXPERIMENTAL): cathodal transcranial direct current stimulation (tDCS)
- anodal stimulation (Type: EXPERIMENTAL): anodal transcranial direct current stimulation (tDCS)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Variable Pressure Support Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Duration of controlled mechanical ventilation ≥ 24h~* Availability of a Infinity V500 ventilator (ready to use)~* Informed consent according to local regulations~* Temperature ≤ 39 °C~* Hemoglobin ≥ 6 g/dl~* PaO2/FIO2 ≥ 150 mmHg with positive end-expiratory pressure (PEEP) ≤16 cmH2O~* Ability to breath spontaneously~Exclusion Criteria:~* Participation in another interventional trial within the last four weeks before enrollment in this trial~* Peripheral neurological disease associated with impairment of the respiratory pump~* Muscular disease associated with impairment of the respiratory pump~* Instable thorax with paradoxical chest wall movement~* Planned surgery under general anesthesia within 72 hours~* Difficult airway/intubation~* Existing tracheotomy at ICU admission~* Expected survival \< 72 hours~* Home mechanical ventilation or on chronic oxygen therapy~* Suspected pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Variable Ventilation (Type: ACTIVE_COMPARATOR): Patients are ventilated with variable pressure support mode.
- Conventional (non-variable) Ventilation (Type: NO_INTERVENTION): Patients are ventilated with non-variable(conventional) pressure support ventilation mode.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a diagnosis of acute myeloid leukemia with the confirmed first or second complete remission~* ≥ 55 years of age~* Not candidates for allogeneic stem cell transplantation as decided by the panel of hematologists at the transplant center~* Patients with a HLA-haploidentical donor who should be able to provide informed consent for peripheral blood apheresis~* No severe concurrent illness that limits life expectancy to less than 2 years~Exclusion Criteria:~* Uncontrolled bacterial or fungal infection at the time of enrollment~* Karnofsky index \<70%~* Acute promyelocytic leukemia~* Other tumor requiring treatment at the time of enrollment~* Active or prior documented autoimmune disease requiring systemic treatment~* Somatic or psychiatric disorder making the patient unable to sign informed consent

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Ara-C+HaploLymphocyte+Nivo (Type: EXPERIMENTAL): Patients treated with nivolumab, intermediate dose cytarabine and haploidentical lymphocyte infusion:~\[Cytarabine 500-1000 mg/m2 bid D-4, -3, -2 + G-CSF mobilized HLA-haploidentical donor peripheral blood stem cells infusion D0~+ Nivolumab 40 mg D+5\] х 2-3 cycles
- Ara-C+ Nivo (Type: EXPERIMENTAL): Patients treated with nivolumab and intermediate dose cytarabine:~\[Cytarabine 500-1000 mg/m2 bid D+1, +2, +3 + Nivolumab 40 mg D+1\] х 2-3 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Performance of the Press Fit Condylar (P.F.C.) Sigma RP-F Knee System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects, aged between 45 and 75 years inclusive.~* Subjects who are able to give voluntary, written informed consent to participate in this investigation and from whom consent has been obtained.~* Subjects who are able to achieve a pre-operative passive range of motion of equal to or greater than 110º.~* Subjects who, in the opinion of the Investigator, are able to understand this investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups.~* Subjects who present with idiopathic osteoarthritis that in the opinion of the clinical investigator requires a primary total knee arthroplasty.~* Subjects who in the opinion of the Clinical Investigator are considered to be suitable for treatment with the P.F.C.® Sigma RPF knee, according to the indications specified in the package insert leaflet.~Exclusion Criteria:~* Subjects who, in the opinion of the Investigator, have an existing condition that would compromise their participation and follow-up in this study.~* Women who are pregnant.~* Subjects who are known drug or alcohol abusers or with psychological disorders that could effect follow-up care or treatment outcomes.~* Subjects who have participated in a clinical study with an investigational product in the last month (30 days).~* Subjects who are currently involved in any personal injury litigation claims.~* Subjects with a known history of poor compliance to medical treatment.~* Subjects who have a pre-operative limb deformity of equal to or greater than 10° varus or 15° valgus as defined using the anatomical axis.~* Subjects who have morbid obesity i.e. BMI ≥40.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- P.F.C. Sigma RP-F Total Knee Replacement (Type: OTHER): An orthopaedic implant for total knee replacement with a mobile-bearing and a high flexion design

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of Navigated Endoscopy for the Placement of High Dose Rate Brachytherapy Applicators in the Esophagus and Lung

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Primary or metastatic cancer including endoluminal disease of either the lung or the esophagus~* Intention to treat using high dose rate brachytherapy as part of standard radiotherapy.~* Ability to provide written informed consent to participate in the study~Exclusion Criteria:~* Contraindications to standard radiation therapy including pregnancy, lactation, connective tissue disorders, serious co-morbid illness~* Concurrent illness or condition that precludes subject from undergoing endoscopy~* Patient is unable to tolerate an hour and a half long procedure. Standard of care practice is no more than 1 hour. However, with the additional tracking component, the procedure could be at most 1.5 hours long.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues